• Enliven outlined plans to start Phase 3 ENABLE-2 in second-line or later CML in 2H 2026, using an 80 mg once-daily dose.
• FDA end-of-Phase 1 feedback supported 80 mg as the Phase 3 dose, a 2L+ population, a physician’s-choice comparator of ATP-competitive TKIs.
• Phase 1b data showed 48% MMR by week 24 at 80 mg once daily; 55% MMR by week 24 in second- and third-line patients.
• Discontinuations due to adverse events ran 6% at 80 mg; 82% of patients remained on study at the data cutoff.
• Cash, cash equivalents, and marketable securities totaled $452 million as of March 31, 2026, providing runway into 1H 2029.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief on June 11, 2026, and is solely responsible for the information contained therein.